# OnCo record tnbc-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/roadmaps/tnbc-roadmap/>
  a schema:CreativeWork ;
  onco:kind "roadmap" ;
  schema:identifier "tnbc-roadmap" ;
  schema:name "Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem"@en ;
  schema:alternateName "TNBC evidence roadmap"@en, "Basal-like breast cancer roadmap"@en, "Triple-negative breast cancer history"@en ;
  schema:description "Triple-negative breast cancer was named for what it lacks, the three receptors other breast cancers are treated through. This roadmap follows it from the receptor discoveries and the basal-like signature of 2000, through chemotherapy, platinum, PARP inhibitors, immunotherapy and antibody-drug conjugates, to the trials asking who can have less and who needs more, with registry dates to 2030."@en ;
  schema:url <https://onco.cc/roadmaps/tnbc-roadmap/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://europepmc.org/article/MED/3798106>, <https://europepmc.org/article/MED/10963602>, <https://europepmc.org/article/MED/12829800>, <https://europepmc.org/article/MED/9145676>, <https://europepmc.org/article/MED/17671126>, <https://europepmc.org/article/MED/16757721>, <https://europepmc.org/article/MED/24149174>, <https://europepmc.org/article/MED/21633166>, <https://europepmc.org/article/MED/22152853>, <https://europepmc.org/article/MED/24529560>, <https://europepmc.org/article/MED/28564564>, <https://europepmc.org/article/MED/42636977>, <https://europepmc.org/article/MED/34097070>, <https://europepmc.org/article/MED/38563834>, <https://europepmc.org/article/MED/36423745>, <https://europepmc.org/article/MED/41937088>, <https://europepmc.org/article/MED/41422862>, <https://europepmc.org/article/MED/38101773>, <https://europepmc.org/article/MED/41072918>, <https://clinicaltrials.gov/study/NCT03036488>, <https://clinicaltrials.gov/study/NCT02032823>, <https://clinicaltrials.gov/study/NCT05374512>, <https://clinicaltrials.gov/study/NCT03997123>, <https://clinicaltrials.gov/study/NCT05812807>, <https://clinicaltrials.gov/study/NCT05929768>, <https://clinicaltrials.gov/study/NCT05633654>, <https://clinicaltrials.gov/study/NCT05629585>, <https://clinicaltrials.gov/study/NCT06103864>, <https://clinicaltrials.gov/study/NCT06926868>, <https://clinicaltrials.gov/study/NCT06382142>, <https://clinicaltrials.gov/study/NCT06419621> ;
  onco:tag "tnbc", "breast", "roadmap" ;
  onco:related <https://onco.cc/roadmaps/tnbc-history/>, <https://onco.cc/roadmaps/trop2-adc-roadmap/>, <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/roadmaps/chemotherapy-roadmap/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/>, <https://onco.cc/roadmaps/ctdna-tests/>, <https://onco.cc/pairings/platinum-plus-hrd/>, <https://onco.cc/pairings/germline-to-parp/>, <https://onco.cc/ideas/idea-tnbc-de-escalation-for-exceptional-responders/>, <https://onco.cc/ideas/idea-tnbc-ctdna-guided-adjuvant-decisions/>, <https://onco.cc/ideas/idea-tnbc-disparities-in-access-and-outcomes/>, <https://onco.cc/ideas/idea-tnbc-pd-l1-assay-harmonisation/>, <https://onco.cc/ideas/idea-tnbc-adc-sequencing-trial/>, <https://onco.cc/ideas/idea-tnbc-brain-metastasis-trials/>, <https://onco.cc/ideas/idea-tnbc-her2-ultralow-testing-uptake/>, <https://onco.cc/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/>, <https://onco.cc/ideas/idea-tnbc-uk-ethnicity-stratified-outcome-reporting/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:sections <https://onco.cc/fronts/adcs/>, <https://onco.cc/fronts/immunotherapy/>, <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/trop2-pet/> ;
  onco:targets <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/akt/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/>, <https://onco.cc/drugs/signatera/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/systimmune/> ;
  onco:institutions <https://onco.cc/institutions/unc-lineberger/>, <https://onco.cc/institutions/md-anderson/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/gbg/>, <https://onco.cc/institutions/royal-marsden/>, <https://onco.cc/institutions/mayo-clinic/>, <https://onco.cc/institutions/nci/>, <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/esmo/>, <https://onco.cc/institutions/asco/> ;
  onco:pathways <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/emt/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/rcb/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/de-escalation/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/brain-metastases/>, <https://onco.cc/terms/adc-sequencing/>, <https://onco.cc/pairings/adc-after-adc-caution/>, <https://onco.cc/terms/pam50/>, <https://onco.cc/terms/anthracycline/>, <https://onco.cc/terms/taxane/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/> ;
  onco:trials <https://onco.cc/trials/keynote-522/>, <https://onco.cc/trials/keynote-355/>, <https://onco.cc/trials/impassion130/>, <https://onco.cc/trials/impassion131/>, <https://onco.cc/trials/impassion031/>, <https://onco.cc/trials/ascent/>, <https://onco.cc/trials/ascent-03/>, <https://onco.cc/trials/ascent-04/>, <https://onco.cc/trials/ascent-05/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/trials/brightness/>, <https://onco.cc/trials/geparsixto/>, <https://onco.cc/trials/tropion-breast01/>, <https://onco.cc/trials/tropion-breast02/>, <https://onco.cc/trials/tropion-breast03/>, <https://onco.cc/trials/tropion-breast05/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/trials/optimice-pcr/>, <https://onco.cc/trials/scarlet-s2212/>, <https://onco.cc/trials/izabright-breast01/>, <https://onco.cc/trials/bl-b01d1-307/>, <https://onco.cc/trials/nct03997123/>, <https://onco.cc/trials/nct06419621/> ;
  onco:people <https://onco.cc/people/peter-schmid/>, <https://onco.cc/people/javier-cortes/>, <https://onco.cc/people/rebecca-dent/>, <https://onco.cc/people/hope-rugo/>, <https://onco.cc/people/sibylle-loibl/>, <https://onco.cc/people/charles-perou/>, <https://onco.cc/people/judy-garber/>, <https://onco.cc/people/andrew-tutt/>, <https://onco.cc/people/nicholas-turner/>, <https://onco.cc/people/sara-tolaney/>, <https://onco.cc/people/aditya-bardia/>, <https://onco.cc/people/jennifer-litton/>, <https://onco.cc/people/mark-robson/>, <https://onco.cc/people/lajos-pusztai/>, <https://onco.cc/people/nancy-lin/>, <https://onco.cc/people/giuseppe-curigliano/>, <https://onco.cc/people/charles-geyer/>, <https://onco.cc/people/gunter-von-minckwitz/>, <https://onco.cc/people/mary-claire-king/>, <https://onco.cc/people/richard-peto/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-diversity/>, <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-brain-delivery/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-negative-results/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-slamon-her2-amplification-science-1987/>, <https://onco.cc/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/>, <https://onco.cc/key-papers/paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003/>, <https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/>, <https://onco.cc/key-papers/paper-dent-tnbc-clinical-features-recurrence-ccr-2007/>, <https://onco.cc/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/>, <https://onco.cc/key-papers/paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014/>, <https://onco.cc/key-papers/paper-lehmann-tnbc-subtypes-jci-2011/>, <https://onco.cc/key-papers/paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008/>, <https://onco.cc/key-papers/paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014/>, <https://onco.cc/key-papers/paper-symmans-j-clin-oncol/>, <https://onco.cc/key-papers/paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022/>, <https://onco.cc/key-papers/paper-geparsixto-lancet-oncol-2014/>, <https://onco.cc/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/>, <https://onco.cc/key-papers/paper-olympiad-nejm-2017/>, <https://onco.cc/key-papers/paper-embraca-n-engl-j-med-2018/>, <https://onco.cc/key-papers/paper-olympia-nejm-2021/>, <https://onco.cc/key-papers/paper-olympia-6-year-update-ann-oncol-2026/>, <https://onco.cc/key-papers/paper-impassion130-n-engl-j-med-2018/>, <https://onco.cc/key-papers/paper-impassion131-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/>, <https://onco.cc/key-papers/paper-keynote-355-nejm-2022/>, <https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2020/>, <https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2024-update/>, <https://onco.cc/key-papers/paper-ascent-nejm-2021/>, <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/key-papers/paper-tropion-breast02-ann-oncol-2026/>, <https://onco.cc/key-papers/paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026/>, <https://onco.cc/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/>, <https://onco.cc/key-papers/paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/>, <https://onco.cc/key-papers/paper-nccn-breast-cancer-v4-2026-jnccn-2026/>, <https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/> .